Get the Stockscreener App
1.15
0.86%
-0.01
After Hours:
1.21
0.06
+5.22%
Aytu Biopharma Inc stock is traded at $1.15, with a volume of 50,160.
It is down -0.86% in the last 24 hours and down -10.85% over the past month.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.
See More
Previous Close:
$1.16
Open:
$1.16
24h Volume:
50,160
Relative Volume:
1.52
Market Cap:
$7.10M
Revenue:
$93.76M
Net Income/Loss:
$-13.68M
P/E Ratio:
-0.4373
EPS:
-2.63
Net Cash Flow:
$8.77M
1W Performance:
-6.88%
1M Performance:
-10.85%
6M Performance:
-52.68%
1Y Performance:
-62.05%
1-Day Range:
$1.15
$1.2038
1-Week Range:
$1.15
$1.25
52-Week Range:
$1.15
$3.4475
Aytu Biopharma Inc Stock (AYTU) Company Profile
Name
Aytu Biopharma Inc
Sector
Phone
(720) 437-6580
Address
7900 E. UNION AVENUE, DENVER
Compare AYTU with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AYTU
Aytu Biopharma Inc
|
1.15 | 7.10M | 93.76M | -13.68M | 8.77M | -2.63 |
|
ZTS
Zoetis Inc
|
163.50 | 72.50B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.98 | 47.08B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.16 | 45.99B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
15.29 | 17.52B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
312.26 | 13.78B | 2.76B | 1.11B | 898.10M | 22.77 |
Aytu Biopharma Inc Stock (AYTU) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-30-21 | Initiated | Cantor Fitzgerald | Overweight |
| May-29-20 | Initiated | H.C. Wainwright | Buy |
Aytu Biopharma Inc Stock (AYTU) Latest News
Vascular Ehlers-Danlos Syndrome Market Growth Projections - openPR.com
Aytu BioPharma Strengthens Leadership Team with Appointment of Richard Eisenstadt as Chief Financial Officer - ACCESS Newswire
AYTU stock touches 52-week low at $1.2 amid market challenges - Investing.com Australia
AYTU BIOSCIENCE, INC : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K) - Marketscreener.com
AYTU stock touches 52-week low at $1.23 amid market challenges - Investing.com Australia
Insider Buying: Joshua Disbrow Acquires 15,000 Shares of Aytu Bi - GuruFocus.com
Aytu Biopharma CEO Joshua Disbrow buys $19,500 in stock - Investing.com India
Aytu Biopharma CEO Joshua Disbrow buys $19,500 in stock By Investing.com - Investing.com South Africa
AYTU BIOPHARMA CEO Acquires 15,000 Shares - TradingView
Aytu BioPharma Reports Second Quarter of Fiscal Year 2023 - ACCESS Newswire
Aytu BioPharma Regains Nasdaq Minimum Bid Price Compliance - ACCESS Newswire
Aytu BioPharma Reports Record Fourth Quarter and Fiscal Year 2022 Revenue - ACCESS Newswire
Earnings call transcript: Aytu BioPharma Q2 2025 sees revenue dip, strategic shifts - MSN
AYTU stock touches 52-week low at $1.3 amid market challenges - Investing.com Australia
AYTU stock touches 52-week low at $1.3 amid market challenges By Investing.com - Investing.com South Africa
Can This New Board Member Transform Evoke Pharma's Commercial Success? - StockTitan
Aytu BioScience and Neos Therapeutics Announce Special Meetings of Stockholders Related to Proposed Merger to Be Held on March 18, 2021 - ACCESS Newswire
Aytu BioPharma anticipates positive cash flow with ADHD growth and $2M annual cost savings - MSN
Aytu BioPharma Ranked Among Fastest-Growing Companies in North America on Deloitte's Technology Fast 500(TM) for Second Year in a Row - ACCESS Newswire
Aytu BioPharma’s Imminent Breakthrough: Can It Reach Profitability? - Mi Valle
Loss-Making Aytu BioPharma, Inc. (NASDAQ:AYTU) Set To Breakeven - Yahoo Finance
Aytu BioPharma Inc (AYTU) Q2 2025 Earnings Call Highlights: Stro - GuruFocus.com
Aytu BioScience Earnings Call: Growth Amid Challenges - TipRanks
Denver biotech cuts $500K check when it parted ways with its CFO - The Business Journals
Aytu BioPharma Inc (AYTU) Q2 2025 Earnings Call Highlights: Strong Cash Position and Strategic ... By GuruFocus - Investing.com Canada
Aytu BioPharma, Inc. (NASDAQ:AYTU) Q2 2025 Earnings Call Transcript - Insider Monkey
Aytu BioPharma Reports Strong Q2 Earnings Growth - TipRanks
Aytu BioPharma Inc. (AYTU) reports earnings - Quartz
AYTU BIOPHARMA, INC SEC 10-Q Report - TradingView
Aytu BioPharma Reports Fiscal 2025 Second Quarter Results - TradingView
Aytu BioPharma Reports Fiscal 2025 Second Quarter Operational and Financial Results - ACCESS Newswire
Aytu BioPharma Turns Profitable: Key Portfolio Growth Drives Q2 Transformation - StockTitan
Aytu BioPharma Reports First Quarter 2022 Financial Results - ACCESS Newswire
Aytu BioPharma to Report Fiscal 2025 Second Quarter Operational and Financial Results on February 12, 2025 - Galveston County Daily News
Aytu BioPharma Earnings Alert: Key Financial Results Coming February 12What to Watch - StockTitan
Aytu BioPharma to Report Fourth Quarter and Full Year Fiscal 2021 Results and Provide Business Update on September 27, 2021 - ACCESS Newswire
Aytu BioPharma to Present at LD Micro Main Event XVI Conference - ACCESS Newswire
Aytu BioPharma Announces Strategic Shift to Focus on Commercial Operations and Indefinite Suspension of Clinical Development Programs - ACCESS Newswire
Aytu BioPharma to Report Fiscal 2025 First Quarter Operational and Financial Results on November 13, 2024 - ACCESS Newswire
Aytu BioPharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024 - ACCESS Newswire
Aytu BioPharma Reports Record ADHD Revenue and Operating Income During Fiscal 2024 Second Quarter - ACCESS Newswire
Aytu BioPharma Announces Initiation of the AR101 PREVEnt Trial for the Treatment of Vascular Ehlers-Danlos Syndrome - ACCESS Newswire
Aytu BioPharma Ranked as One of Fastest-Growing Companies in North America on the 2024 Deloitte Technology Fast 500(TM) - ACCESS Newswire
Aytu BioPharma Announces the Passing of Co-Founder and Board Member Michael Macaluso - ACCESS Newswire
Aytu BioPharma Ranked Among Fastest-Growing Companies in North America on Deloitte's Technology Fast 500(TM) for Third Consecutive Year - ACCESS Newswire
Aytu BioPharma Announces Closing of $4.0 Million Public Offering Priced At-the-Market - ACCESS Newswire
Aytu BioPharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025 - ACCESS Newswire
Aytu BioPharma Announces Exclusive Agreement with Lupin Pharma Canada Ltd to Commercialize Adzenys XR-ODT(R) and Cotempla XR-ODT(R) in Canada - ACCESS Newswire
Aytu BioPharma Announces Sale of Consumer Health Business Following Wind Down of Consumer Health Operations - ACCESS Newswire
Aytu BioPharma Reports Fiscal 2024 First Quarter Financial Results - ACCESS Newswire
Aytu BioScience Completes Acquisition of Innovus Pharmaceuticals - ACCESS Newswire
Aytu Biopharma Inc Stock (AYTU) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.06%
0.52%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):